INTENDED FOR UK HEALTHCARE PROFESSIONALS

OUR PRODUCTS >

ATIMOS®

Asthma: Licensed in adults and
adolescents 12 years and above
COPD: Licensed in adults
18 years and above

OVERVIEW – ATIMOS® pMDI

Atimos® is available in a pressurised metered-dose inhaler (pMDI), delivering 100 inhalations of 12 micrograms of formoterol fumarate dihydrate per device.

Indications for Atimos®1

Asthma
For the long-term symptomatic treatment of persistent, moderate to severe asthma in patients requiring regular bronchodilator therapy in combination with long-term anti-inflammatory therapy (inhaled and/or oral glucocorticoids).

Glucocorticoid therapy should be continued on a regular basis.

COPD
Atimos® is indicated for the relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD).

Reference:

  1. Atimos Summary of Product Characteristics. Chiesi Limited.